AB-BIOTICS

Trading sesion


01/12/2016 Close

1.6000

Last price


20.14 mill. €

Capitalisation

0.00

Dif.(%)


-19.19

% Year 2016

Last Trade

Last

1.6000

Ref.

1.6000

Dif.(%)

0.00

Volume (Shares)

2,224

Turnover (€x1000)

6.00

Security

Security name

AB-BIOTICS

Ticker

ABB

ISIN

ES0109659013

NIF

A-63497473

Capital Admitted

629.412,95 Euros

Shares Admitted

12.588.259

Nominal

0,05 Euros

Trading

Fixing

Liquidity Provider

GVC GAESCO BEKA, S.V., S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

KPMG AUDITORES, S.L

Address

AV/ DE LA TORRE BLANCA 57, 08173 SANT CUGAT DEL VALLÉS

Contact

info@ab-biotics.com

Historical Summary

 20122013201420152016 until 5/12

Capital Admitted (thousands of euros)

353480480480629

Shares (x 1,000)

7,0699,5969,5969,59612,588

Period Close Price (euros)

2.10002.25001.77001.98001.6000

Period Last Price (euros)

2.10002.25001.77001.98001.6000

Period High Price (euros)

2.84002.30003.83002.51001.9500

Period Low Price (euros)

1.74001.33001.55001.77001.3000

Capitalisation (thousands of euros)

14,84521,59116,98519,00020,141

Volume (thousands of shares)

7146702,170901613

Turnover (thousands of euros)

1,7421,3135,8991,9541,016

Company Profile

AB-BIOTICS is a Spanish company founded in Barcelona in 2004, leading Biotechnology and whose activity is diversified into two business areas based on the research, development, protection and distribution of biotech own unique solutions, with a mission to improve the health and wellbeing of people.

AB-BIOTICS has an innovative philosophy and has a know-how that allows itself to develop cutting-edge products that provide high added value to market. The AB-BIOTICS projects offer the pharmaceutical and food products greater efficiency and help to improve the health of people while helping reduce health care costs.

AB-BIOTICS is organized into two business areas:

  1. NEUROFARMAGEN (AB-GENOTYPING): focuses on the development of genetic analysis to develop pharmacogenetic studies (the way in which patients will respond to different treatments and drugs, based on their genetic inheritance) which provide more information to doctors about the most effective treatments and appropriate dose for each patient (personalized medicine).
     
  2. AB-BIOTICS FUNCTIONAL INGREDIENTS: probiotics and other nutraceuticals are developed for the pharmaceutical industry and food industries. These functional ingredients are useful for the prevention and treatment of a wide range of illnesses, from cardiovascular to infantile colic, among others.

AB-BIOTICS has a multidisciplinary team led by CEOs Miquel Angel Bonachera and Sergi Audivert. D. Luis Sanchez-Lafuente is the President of the Company. The organization combines the talents of young, dynamic and highly qualified professionals with extensive international experience and success in business and biotechnology. 

Relevant Facts and Notices

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.

Copyright © Bolsas y Mercados Españoles 2016. All rights reserved. Disclaimer // Legal Disclaimer // Suppliers payment period